NCT06324045

Deprescribing Intervention for Patients With Chronic Kidney Disease

Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial
Hamad Medical Corporation·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Chronic Kidney Diseases
Drug/Device/Intervention
Deprescribing
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Hamad Medical Corporation
Location
Doha, Qatar
Timeline & enrollment
Phase
N/A
Start date
Feb 19, 2024
End date
Aug 31, 2025
Enrollment
424 participants
Primary outcome

Percentage of participants with at least one Potentially inappropriate medications (PIMs),Number of Potentially inappropriate medications (PIMs)

Summary

Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is
 associated with multiple consequences such as cardiovascular diseases, infections, reduced
 cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the
 population suffers from CKD. Management of CKD is associated with polypharmacy (the use of
 multiple medications), which burdens the patients and leads to adverse health and economic
 outcomes. As documented by previous studies, CKD setting is associated with a high medication
 burden, which leads to non-adherence, reduced quality of life, and other negative sequelae.
 These consequences can be minimized or averted by implementing a deprescribing program.
 Deprescribing is defined as the supervised process of intentionally stopping a medication,
 altering the dose or introducing a safer alternative to improve a person's clinical and
 quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient
 hospital settings were successfully implemented.
 
 In general, there are limited deprescribing initiatives in CKD settings. There is a need to
 provide evidence of the impact of deprescribing programs on improving clinical and economic
 outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing
 deprescribing programs in clinical settings. Therefore, we have built a team of researchers,
 clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit
 into the Qatar healthcare system. This project aims to initiate a deprescribing
 multidisciplinary team and to evaluate the impact of providing such services on the clinical
 and economic outcomes among CKD patients in Qatar using a randomized controlled trial
 approach. The findings could have a potential positive impact on the professional practice
 and patient safety represented by health and economic outcomes.

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06324045
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06324045 through Pure Global AI's free database. This phase not specified trial is sponsored by Hamad Medical Corporation and is currently Recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 424 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.